Explore the vast range of titles available.

Few studies have analyzed compulsive buying behavior in relation to a specific product. Smartphones are hugely popular products today, especially among young people. These two aspects have motivated this research into the compulsive buying behavior of Smartphones by university students. To study this behavior, the main features that differentiate compulsive buyers from those that are not are analyzed, and their risk profiles are obtained through a discrete choice model. Sociodemographic features that define buyers with the greatest propensity to compulsiveness are younger age, longer time spent daily using social networks, higher spending on the acquisition of Smartphones and having owned a greater number of these devices. These buyers also show shopping addiction and greater feelings of guilt after the purchase as well as more positive and negative affective states when purchasing Smartphones. This analysis not only determines the characteristics that define young individuals with a tendency toward compulsiveness in Smartphone purchases, but also contributes to quantifying the probability of having this tendency.

Objective To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical practice in von Willebrand Disease (VWD) patients. Methods A retrospective, multicentric, observational study of VWD patients treated with Fanhdi®, a pdVWF/FVIII concentrate, from January 2011 to December 2017 was conducted at 14 centers in Spain. Efficacy and safety were evaluated for acute bleeding episodes, for prevention of bleeding in surgeries, and for secondary long-term prophylaxis. Results Seventy-two eligible patients, type 1, 2, 3 VWD (25%/38.9%/36.1%) were treated for spontaneous and traumatic bleeding (140 episodes, n = 41 patients), to prevent surgical bleeding (69 episodes, n = 43 patients); and for secondary long-term prophylaxis (18 programs, n = 13 patients). Replacement therapy with pdVWF/FVIII showed an excellent to good clinical efficacy in 96.7% of the bleeding episodes, 100% during surgical procedures and 100% during prophylaxis. No adverse events (AEs), nor serious AEs related to the product were observed. Conclusions Fanhdi® was effective, safe and well tolerated in the management of bleeding episodes, the prevention of bleeding during surgeries, and for secondary long-term prophylaxis in VWD patients.

Objetivo Conocer la evidencia sobre los factores relacionados con la fatiga por compasión entre profesionales sanitarios de oncología y cuidados paliativos. Metodología Revisión sistemática. Estrategia de búsqueda en bases de datos Pubmed, Cuiden, Cinahl y Psycinfo. Resultados La fatiga por compasión ha sido relacionada con el Síndrome de burnout y correlacionada negativamente con la satisfacción por compasión. El nivel de fatiga por compasión varía entre profesionales siendo mayor en enfermeros y médicos. Factores como el autocuidado, las condiciones laborales y la salud del trabajador repercuten en su desarrollo. Las estrategias de prevención se focalizan en el empoderamiento del profesional sanitario, formación y la oferta de periodos de retiro. Conclusiones Es necesario fomentar la concienciación en el personal sanitario sobre los problemas psicológicos que pueden experimentarse como consecuencia de la atención a personas en situación paliativa, así como fomentar su prevención y abordaje a través de la implantación de diferentes intervenciones.

Background and objectives: The incidence of obesity during pregnancy is increasing. Early programming of obesity could take place since very early stages of life, even during gestation. However, little is known about the mechanisms involved in this process. Our aim was to investigate the in vivo metabolism and placental transfer of fatty acids (FA) labelled with stable isotopes across the placenta in obese and normal weight pregnant women. Methods: 10 controls (BMI 20-25kg/m2) and 10 obese pregnant women (BMI >30kg/m2) received orally, 12h before elective caesarean section, 0.05mg/kg 13C-oleic acid (13C-OA), 0.05mg/ kg 13C-linoleic acid (13C-LA) and 0.01mg/kg 13C-docosahexaenoic acid (13C-DHA). Maternal blood was collected at -8h, -4h, -2h and at time of caesarean section; placental tissue and cord blood were also collected at delivery. VLDL, LDL and HDL were isolated by ultracentrifugation. Lipid fractions from serum and placenta were isolated by thing layer chromatography. All samples were analysed for 13C enrichment by gas chromatography combustion isotope ratio mass spectrometry (GC-C-IRMS). Results: Both maternal serum triglycerides and cholesterol levels were similar in obese and normal weight pregnant women. Maternal insulin, placental weight and cord glucose tended to higher values in the obese group (n.s.). Both DHA and LA were significantly higher in plasma non-esterified fatty acids in obese vs. normal weight women (LA: 1.19 ± 0.16% vs. 0.83 ± 0.08%, P=0.058, DHA: 0.18 ± 0.04% vs. 0.09 ± 0.01%, P=0.046). HDL and LDL lipoproteins showed higher enrichment of LA and especially of DHA in the obese group, which may affect placental uptake of these FA. Tracer concentrations in total lipids of placenta were similar in both groups. However, the FA transfer to the fetus, evaluated by the ratio between cord and maternal 13C-FA plasma concentrations, was lower in obese women compared to controls, with a significant difference for LA (0.25 ± 0.03% vs. 0.39 ± 0.06%, P=0.04). Conclusions: The materno-fetal placental fatty acid transfer of LA and DHA is lower in obese pregnant women without hyperlipidemia than in women with normal body weight.

Hydroxyurea (HU) constitutes the first-line treatment in most patients with essential thrombocythemia (ET), but criteria for changing therapy are not clearly established. The prognostic value of complete hematological response (CHR) and resistance/intolerance to HU was assessed in 1080 patients from the Spanish Registry of ET, classified according to revised IPSET-Thrombosis stratification (Very low- n  = 61, Low- n  = 83, Intermediate- n  = 261, and High-risk n  = 675). With a median therapy duration of 5 years, CHR was registered in 720 (67%) patients (1-year probability 51%) and resistance/intolerance in 219 (20%) patients (5-years probability 13%). After correction by other risk factors, High-risk patients achieving CHR showed a reduced risk of arterial thrombosis (HR: 0.35, 95%CI: 0.2–0.6, p  = 0.001) and a trend towards lower risk of venous thrombosis (HR: 0.45, 95%CI: 0.2–1.02, p  = 0.06) whereas no association was observed for intermediate- or low-risk patients. In comparison with non-responders, intermediate- and high-risk patients achieving CHR had longer survival and lower myelofibrosis incidence. Development of resistance/intolerance to HU, mainly cytopenia, was associated with higher probability of myelofibrosis but no effect on survival or thrombotic risk was demonstrated. In conclusion, CHR with HU is associated with better outcomes and might be an early indicator for selecting candidates to second-line clinical trials.

Cytogenetic assessment in myelofibrosis is essential for risk stratification and patient management. However, an informative karyotype is unavailable in a significant proportion of patients. Optical genome mapping (OGM) is a promising technique that allows for a high-resolution assessment of chromosomal aberrations (structural variants, copy number variants, and loss of heterozygosity) in a single workflow. In this study, peripheral blood samples from a series of 21 myelofibrosis patients were analyzed via OGM. We assessed the clinical impact of the application of OGM for disease risk stratification using the DIPSS-plus, GIPSS, and MIPSS70+v2 prognostic scores compared with the standard-of-care approach. OGM, in combination with NGS, allowed for risk classification in all cases, compared to only 52% when conventional techniques were used. Cases with unsuccessful karyotypes (n = 10) using conventional techniques were fully characterized using OGM. In total, 19 additional cryptic aberrations were identified in 9 out of 21 patients (43%). No alterations were found via OGM in 4/21 patients with previously normal karyotypes. OGM upgraded the risk category for three patients with available karyotypes. This is the first study using OGM in myelofibrosis. Our data support that OGM is a valuable tool that can greatly contribute to improve disease risk stratification in myelofibrosis patients.

Este trabajo se inserta dentro del debate acerca de si las diferencias de rendimientos de las empresas son la consecuencia de las características propias de las mismas y/o del sector en el que desarrollan su actividad. En este sentido, el objetivo de este trabajo es contrastar empíricamente la importancia del tamaño empresarial y del sector de actividad a la hora de explicar la variabilidad de la rentabilidad. El análisis lo realizamos sobre una muestra amplia de empresas canarias, fundamentalmente pequeñas y medianas para el período 1990-94, pertenecientes a diversos sectores de actividad. Los resultados obtenidos son consistentes con otros trabajos realizados en nuestro país, y apuntan a la ausencia de efecto del tamaño empresarial sobre la rentabilidad económica, lo cual sugiere la conveniencia de analizar otros factores específicos de la empresa que sean capaces de explicar en mayor medida las disparidades de rentabilidades interempresas. Sin embargo, hemos podido constatar que el sector de actividad en el que se desenvuelve la empresa explica una parte de la variabilidad observada en la rentabilidad, sin que podamos observar interacción entre tamaño y sector de actividad. This paper is inserted inside the discussion about whether firm's profitability differences are the consequence of business-specific factors and/or industry factors. In this sense, the objective of this study is to test empirically the importance of the dimension and of the sector in explaining the profitability managerial variability. The analysis was carried out in a wide sample of Canary firms, mainly small and medium firms, for the period 1990-94, belonging to diverse activity sectors. The results are consistent with other works carried out in our country, and they point to the absence of size effect on the economic profitability, that suggests the convenience of analyzing other specific factors of the firm that wil be able to explain better the disparities of profitabilities interfirms. However, we have been able to verify that the industry explains a part of the variability observed in the profitability, although we cannot observe any relation between size and activity sector.